KAMALESH RAO, Founder and Chief Executive Officer
Kamalesh has over 20 years of experience in drug discovery and development of pharmaceuticals, implant dosage development, and product approvals. He played a pivotal role in the chemical development of botanical product approved by USFDA and Probuphine®, first ever implantable formulation to deliver long-lasting medication to treat people addicted to opioids. He has directed the chemical development of more than 10 New Chemical Entities.
DR. SADHANA SATHAYE, Chief Scientific Officer
Dr. Sathaye has extensive experience in pharmacokinetics, pharmacodynamics, drug development, and formulation development. Sadhana has authored over 75 publications in national and international journals. She is currently Professor of Pharmacology at the Institute of Chemical Technology (ICT) in Mumbai and consultant to the company.
DR. VIDYA HEBBAR, Vice President, Product Development
Dr. Hebbar has a PhD in Pharmaceutical Sciences and is a Registered Pharmacist. She has experience in conducting drug utilization reviews, product labeling review, adverse event investigation and reporting, and target identification for repurposing.
JERRY O’LEARY, Chief Financial Officer
Jerry has management and consulting experience as a senior manager in the financial services industry, consulting experience with public accounting organization, and as member of boards. Jerry is a CPA by training and managed securities services for Chemical Bank that was later acquired by JP Morgan. He is a board Member and an adviser for several organizations.
DR. PURNIMA AMIN, Scientific Advisor
Dr. Amin is Professor of Pharmacy at the Institute Of Chemical Technology. She is a recognized industry expert in Hot Melt Extrusion (HME), solid dosage forms, and bioavailability enhancement. Purnima is advising and assisting in the development of drug delivery platforms based on HME to develop long acting injectables and related sustained delivery platforms.
DR. USHA NAYAK, Scientific Advisor
Dr. Nayak is a Professor at Manipal College of Pharmaceutical Sciences. She is an expert in nano-pharmaceuticals, controlled drug delivery, and bioavailability enhancement. Usha is advising and assisting the company in development of long acting injectables and related sustained-release drug delivery platforms.
DR. WILLIAM BAKER, Scientific Advisor
Dr. Baker, DVM is the President of William J. Baker, LLC, where he provides consultative advice regarding the development of veterinary drugs. Bill has 23 years of experience in veterinary medicine research and development, working in Pfizer Animal Health/Zoetis. During his career, Bill led regulatory affairs, and clinical development. He retired as a Vice-President in 2017, when he started his consulting business.